Endo- and myocarditis as a severe complication of immune-related adverse event treatment: a case report.

Background: Disseminated infection is a severe condition in immunocompromised patients. Mortality secondary to cardiac infection remains high.

Case Summary: We present a case of a 45-year-old female breast cancer patient who developed endocarditis and myocarditis after receiving the immune checkpoint inhibitor (ICI) pembrolizumab.

Comparison of femoral triangle plus iPACK blocks with femoral triangle block alone for anterior cruciate ligament reconstruction: a randomized controlled clinical trial on postoperative pain and knee function.

Background: Anterior cruciate ligament reconstruction (ACLR) can cause severe postoperative pain. However, consensus regarding the most effective regional analgesia is lacking. We hypothesized that, compared with femoral triangle block (FTB) and local infiltration analgesia, adding an iPACK block would decrease postoperative morphine consumption.

Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.

Background/purpose: Normal tissue complication probability (NTCP) models can be used to guide radiation therapy (RT) decisions by estimating side-effect risks pretreatment to minimize (late) side-effects. Recently, a comprehensive individual toxicity risk (CITOR) profile of NTCP models addressing common side-effects in head and neck cancer (HNC) patients was developed. This study investigates the generalizability of these models in an international setting, with different treatment approaches and side-effect assessments, promoting their integration into more widespread clinical practice.

Sporadic ALS hiPSC-derived motor neurons show axonal defects linked to altered axon guidance pathways.

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by the selective and progressive loss of motor neurons, leading to gradual paralysis and death within 2 to 5 years after diagnosis. The exact underlying pathogenic mechanism(s) remain elusive. This is particularly the case for sporadic ALS (sALS), representing 90 % of cases, as modelling a sporadic disease is extremely difficult.

Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications.

Autosomal dominant mutations in the gene encoding the DNA and RNA binding protein FUS are a cause of amyotrophic lateral sclerosis (ALS), and about 0·3-0·9% of patients with ALS are FUS mutation carriers. FUS-mutation-associated ALS (FUS-ALS) is characterised by early onset and rapid progression, compared with other forms of ALS. However, different pathogenic mutations in FUS can result in markedly different age at symptom onset and rate of disease progression.